NCT04841759 is a NA clinical trial of Exercise in COVID-19, sponsored by Medical University of Vienna.

Who is sponsoring NCT04841759?

NCT04841759 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT04841759?

Interventions in NCT04841759: Exercise.

Is NCT04841759 still recruiting?

NCT04841759 is currently completed. Last updated 27 December 2021.

Last reviewed 2021-12-27 · How we verify

NCT04841759

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue Syndrome

Completed NA Last updated 27 December 2021

What this trial tests

NA trial testing Exercise in COVID-19 in 46 participants. Completed in 22 December 2021.

Timeline

1 April 2021

Primary endpoint
3 December 2021

22 December 2021

Quick facts

Lead sponsor	Medical University of Vienna
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	46
Start date	1 April 2021
Primary completion	3 December 2021
Estimated completion	22 December 2021
Sites	1 location across Austria

Drugs / interventions tested

Exercise

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Medical University of Vienna

Who can join

Adults 18 to 65, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The SARS-CoV2 pandemic has kept the world in suspense for over a year now. Almost 100 million people around the world have contracted COVID-19 to date and over 2 million people have died of COVID-19 by the end of January 2021. Despite the tragedy of these deaths, it must be pointed out at this point that the number of COVID-19 survivors is significantly larger. These COVID-19 survivors are now the focus of interest in rehabilitation measures, as it has been shown that survival of the disease does not go hand in hand with a complete cure. Thirty-five percent of all COVID-19 survivors and 87% of the COVID-19 survivors who were hospitalized in the course of their illness suffer from after-effects that are currently summarized as post-COVID fatigue syndrome also known as "Long-COVID". As health care workers are at higher risk of contracting SARS CoV2 and furthermore, considering their central role in the overcoming of this pandemic, a COVID-19 rehabilitation program for healthcare workers of the Medical University of Vienna, Austria as well as the General Hospital of Vienna, Austria - together the second-largest university-clinic in the world - was developed as part of workplace health promotion. Nowadays, the fatigue syndrome is primarily known as a side effect of cancer treatment and thus from the rehabilitation of cancer patients. Cancer-related fatigue is a massive limiting side effect for patients and the currently most effective treatment strategy against cancer-associated fatigue syndrome is physical training. The idea for this current project is, that physical exercise might have similar effects on post-SARS-CoV2 fatigue as it has on cancer-related fatigue. The current study evaluates the effects of this primarily exercise-based rehabilitation program on Long-COVID fatigue.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research.
Ceban F, Leber A, Jawad MY, Yu M, et al · · 2022 · cited 52× · PMID 35282780 · DOI 10.1080/23744235.2022.2043560
Exercise program for the management of anxiety and depression in adults and elderly subjects: Is it applicable to patients with post-covid-19 condition? A systematic review and meta-analysis.
Piva T, Masotti S, Raisi A, Zerbini V, et al · · 2023 · cited 22× · PMID 36634854 · DOI 10.1016/j.jad.2022.12.155
At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease.
Cascino TM, Desai AA, Kanthi Y. · · 2021 · cited 10× · PMID 34127622 · DOI 10.1097/mcp.0000000000000792
Long COVID Symptom Management Through Self-Care and Nonprescription Treatment Options: A Narrative Review.
Kachroo P, Boivin G, Cowling BJ, Shannon W, et al · · 2025 · PMID 41007506 · DOI 10.3390/ijerph22091362
Facilitators and barriers of long-term exercise adherence in healthcare workers formerly suffering from post-COVID-19 syndrome : A qualitative 1-year follow-up and quantitative pilot study of the COFIT trial.
Hasenöhrl T, Scharer B, Steiner M, Schmeckenbecher J, et al · · 2024 · PMID 39367278 · DOI 10.1007/s00508-024-02446-x

Verify or expand the search:

Other trials of Exercise

Trials testing the same drug.

NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
NCT07007858 — Effects of High-Velocity Passive Stretch on Spasticity, Function, and Muscle Structure in Spastic CP Children · NA · enrolling by invitation
NCT07589725 — Mulligan Mobilization in Lateral Elbow Tendinopathy · NA · not yet recruiting
NCT07524400 — Effects of Physical Exercise Combined With Transcranial Direct Current Stimulation in Parkinson's Disease · NA · recruiting
NCT06627569 — Exercise Effects on the Neurobiology Underlying Stress-related Eating Behaviors in Veterans · NA · not yet recruiting

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04841759 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 27 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04841759.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing